Nomura Holdings’s Aspire Biopharma Warrant ASBPW Stock Holding History

Nomura Holdings’s Portfolio ASBPW Stock Details ASBPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-150,000	Closed	-$4.5K	–	2229
2025 Q3	$4.5K	Hold	150,000	–	–	﹤0.01%	1833
2025 Q2	$6.75K	Buy	+150,000	New	+$7.41K	﹤0.01%	1378
2025 Q1	–	Sell	-150,000	Closed	-$7.2K	–	2472
2024 Q4	$7.2K	Hold	150,000	–	–	﹤0.01%	2135
2024 Q3	$6.3K	Hold	150,000	–	–	﹤0.01%	1484
2024 Q2	$4.5K	Hold	150,000	–	–	﹤0.01%	1725
2024 Q1	$4.5K	Hold	150,000	–	–	﹤0.01%	1574
2023 Q4	$9.07K	Hold	150,000	–	–	﹤0.01%	1724
2023 Q3	$10.9K	Hold	150,000	–	–	﹤0.01%	1329
2023 Q2	$7.5K	Hold	150,000	–	–	﹤0.01%	1299
2023 Q1	$7.5K	Hold	150,000	–	–	﹤0.01%	1390
2022 Q4	$11K	Hold	150,000	–	–	﹤0.01%	1362
2022 Q3	$20K	Hold	150,000	–	–	﹤0.01%	1481
2022 Q2	$21K	Buy	+150,000	New	+$32.6K	﹤0.01%	1599

Other funds holding ASBPW

MTCM

Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.5% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Nomura Holdings's ASBPW Position: Q4 2025 in Review

Nomura Holdings sold out of Aspire Biopharma Warrant (ASBPW) in Q4 2025, closing a stake of 150,000 shares — an estimated $4.5K sold.

Nomura Holdings first reported a position in ASBPW in Q2 2022 and held it in 13 quarters. The position peaked at $21K in Q2 2022. 29 funds tracked by Wall St. Rank hold ASBPW as of Q4 2025.

Nomura Holdings reported no remaining Aspire Biopharma Warrant position as of Q4 2025 after selling out during the quarter.
Nomura Holdings sold 150,000 Aspire Biopharma Warrant shares in Q4 2025, an estimated $4.5K.
Nomura Holdings first reported a position in Aspire Biopharma Warrant in Q2 2022 and held it in 13 quarters.
Nomura Holdings's Aspire Biopharma Warrant position peaked at $21K in Q2 2022.
29 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q4 2025.

Based on Nomura Holdings's 13F filing for Q4 2025, filed 17 Feb 2026.